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ABSTRACT
Objective: To examine women’s preferences for characteristics of chlamy-
dia screening. Chlamydia trachomatis is the most common curable sexu-
ally transmitted disease. To design effective screening programs, it is
important to fully capture the beneﬁts of screening to patients. Thus, the
value of experience factors must be considered alongside health outcomes.
Methods: A self-complete discrete choice experiment questionnaire was
administered to women attending a family planning clinic. Chlamydia
screening was described by ﬁve characteristics: location of screening; type
of screening test; cost of screening test; risk of developing pelvic inﬂam-
matory disease if chlamydia is untreated; and support provided when
receiving results.
Results: One hundred twenty-six women completed the questionnaire.
Respondents valued characteristics of the care experience. Screening was
valued at £15; less invasive screening tests increase willingness to pay by
£7, and more invasive tests reduce willingness to pay by £3.50. The most
preferred screening location was the family planning clinic, valued at £5.
The support of a trained health-care professional when receiving results
was valued at £4. Respondents under 25 years and those in a casual
relationship were less likely to be screened.
Conclusions: Women valued experience factors in the provision of chlamy-
dia screening. To correctly value these screening programs and to predict
uptake, cost-effectiveness studies should take such values into account.
Failure to do this may result in incorrect policy recommendations.
Keywords: chlamydia screening, discrete choice experiments, take-up
rates, willingness to pay.
Background
Chlamydia trachomatis is the most common curable sexually
transmitted disease [1]. Although estimated prevalence rates vary
across studies and countries, prevalence is highest among under
25-year-olds [2]. In the United Kingdom, the United States, and
Canada, the prevalence of chlamydia is increasing [3–5].
Chlamydia infection is treated with inexpensive antibiotics [6].
Nevertheless, infection is asymptomatic in 75% of women
and 50% of men [7]. Thus, prevalence control depends on
population-based screening.
In line with many economic evaluations, a recent systematic
review found that cost-effectiveness studies of chlamydia screen-
ing have focused on health outcomes [2]. Nevertheless, experi-
ence factors associated with health care are also valued by
individuals. Such factors for chlamydia screening may include the
location of screening, type of test, and whether support is pro-
vided. To fully capture the beneﬁts of screening to patients and to
enable predictions of take-up rates, the value of experience
factors must be considered alongside health outcomes. This study
aims to do this using a discrete choice experiment (DCE) [8].
Methods
Subjects were recruited from women attending a family planning
clinic in Aberdeen, Scotland during June and July 2002. Subjects,
who were not attending the clinic for chlamydia screening, were
asked to participate in the study on their arrival. Those who
agreed received an information sheet about chlamydia and a
questionnaire to complete while waiting for their appointment.
These are available from the authors upon request. The question-
naire elicited respondents’ preferences for chlamydia screening
using a DCE. Information was also collected on respondents’
demographic characteristics such as age, education, income, rela-
tionship status, and indicators of health behavior (smoking and
method of contraception used) to help understand preferences.
Ethical approval was granted by the Grampian ethics committee.
Based on a literature review, policy variations, and advice
from the family planning clinic’s doctor, ﬁve screening attributes
were identiﬁed. These represent experience factors that vary
across available screening tests in the United Kingdom. The
attributes and levels are presented in Table 1 (column 1). The
range of the levels for the cost attribute was determined using a
contingent valuation study. The experimental design software
(SPEED Hague Consulting, The Hague, The Netherlands) pro-
duced a fractional factorial design of 16 proﬁles. Each proﬁle was
presented as a hypothetical test, and respondents were asked if
they would be screened: possible responses were “yes” or “no.”
This binary method of preference elicitation maintains the design
properties of orthogonality and level balance [8].
The data were analyzed using a logit model. Model 1 includes
the ﬁve screening attributes and model 2 includes interaction
terms. Two income/cost interaction terms were included
(<£15,000 and£15,000). Respondentswith lower incomeswere
predicted to have a higher marginal utility of income, thus placing
more importance on the price proxy. A Wald test was used to test
if the interaction termswere signiﬁcantly different, thus testing the
theoretical validity of the model. Respondents’ age, relationship
status, contraception method, and whether they smoked (as a
proxy for risky health behavior) were interacted with the constant
term to test if such factors inﬂuenced the overall preference to be
screened. The logit model results were used to calculate the
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marginal willingness to pay (WTP) for a unit change in each
attribute and to predict uptake for alternative screening tests.
Results
One hundred seventy-four respondents were recruited, 25 did
not complete any of the DCE, leaving a sample size of 149.
Table 2 summarizes the respondents’ characteristics. Although
information was not collected on those who did not participate,
83% of respondents were less than 25 years old: the target
population for screening programs.
Table 1 (columns 2–5) presents the DCE results. In model 1,
the positive and signiﬁcant constant term indicates a general
preference to be screened. The general practitioner and genitouri-
nary medicine (GUM) clinic locations are not signiﬁcant, indicat-
ing that screening at these locations does not inﬂuence the overall
preference for screening. Screening at the family planning clinic is
signiﬁcant and positive; this indicates that this location increases
the general preference for screening. Screening at home is signiﬁ-
cant and negative; this indicates that this location decreases the
general preference for screening. A urine test and having the
support of a trained health-care advisor are both signiﬁcant and
positive. As expected, more invasive tests (perineal swab and full
pelvic examination) and cost are signiﬁcant and negative, imply-
ing a negative effect on screening preference.
Model 2 presents the results with interaction terms. The cost
coefﬁcient is signiﬁcantly different across low- and high-income
groups, indicating that higher-income respondents have a lower
marginal utility of money, and therefore higher marginal WTP.
Respondents who are younger than 25 and those in a casual
relationship (compared to single or permanent) have lower
screening propensities. Smokers are more likely to be screened,
and using a barrier method of contraception was not signiﬁcant.
Table 1 (columns 6 and 7) reports the marginalWTP for a unit
change in each attribute. These results echo those reported earlier.
For example, respondents are prepared pay £15.23 for screening.
Screening at the family planning clinic increases WTP by £5.31, a
urine test increases WTP by £7.09, and having a health-care
advisor support increases WTP by £4.26. Screening at home
reduces WTP by £4.14, and having a perineal swab or full pelvic
examination reduces WTP by £3.50 and £3.57, respectively.
Using model 1, the predicted uptake of a urine test at the
family planning clinic with support is 91%. This is higher than
the predicted uptake for the two tests used by Low et al. to assess
the cost-effectiveness of chlamydia screening [2]: screening at
home, with trained health-care advisor support using a urine test
(83%) or a perineal swab (70%). Traditionally, screening is
offered at GUM clinics; here, the predicted uptake for a urine test
with support is 87%.
Conclusions
The prevalence of sexually transmitted infections continues to
be a public health concern, thus an acceptable screening strat-
egy must be devised. This study elicited preferences of the
target screening population for characteristics of chlamydia
screening tests. Women attending a family planning clinic pre-
ferred to be screened using less invasive tests and valued the
Table 1 Discrete choice experiment: attributes, levels, regression results, and marginal WTP
Attributes and levels
Model 1 Model 2 Interaction terms
WTP mean (£)
WTP 95% conﬁdence
interval*Coefﬁcient t statistic Coefﬁcient t statistic
Place of screening
Family planning clinic† 0.377 4.50 0.369 4.12 5.32 5.24, 5.40
General practitioner -0.096 -1.12 -0.081 -0.88 ‡ ‡
GUM clinic 0.014 0.16 0.032 0.35 ‡ ‡
Home -0.295 -3.69 -0.321 -3.74 -4.14 -4.22, -4.07
Type of screening
Urine test† 0.500 7.04 0.545 7.15 7.09 7.02, 7.16
Perineal swab -0.249 -3.49 -0.295 -3.84 -3.51 -3.57, -3.45
Full pelvic examination -0.250 -3.55 -0.249 -3.31 -3.58 -3.64, -3.52
Cost of screening (£)
(£0, £5, £10, £25) -0.071 -11.00 — — — —
Cost ¥ Income < £15,000 — — -0.077§ -9.28 — —
Cost ¥ Income > £15,000 — — -0.065§ -7.87 — —
Risk of PID (%)
(0%, 5%, 10%, 25%) 0.002 0.38 0.004 0.63 ‡ ‡
Support of a trained
health-care advisor
Yes 0.304 5.54 0.366 6.14 4.26 4.22, 4.31
No† -0.304 -5.54 -0.366 -6.14 -4.26 -4.22, -4.31
Constant 1.082 11.85 1.308 7.43 15.23 15.15, 1531
Less than 25 years old|| — — -0.309 -2.00 — —
In casual relationship|| — — -0.255 -2.08 — —
Use barrier contraception|| — — -0.002 -0.02 — —
Smoker|| — — 0.199 1.94 — —
Number of observations 2142 1895
Number of respondents 149 141
c2 (df) 205.83 207.59
McFadden’s R* 0.074 0.085
*Conﬁdence intervals are calculated using bootstrapping.
†Using effects coding L-1 levels are calculated using the regression model, the missing level can be obtained using the formula b4 = (-1 ¥ b1) + (-1 ¥ b2) + (-1 ¥ b3). Furthermore, the standard
error of the missing level is calculated as the average of the L-1 parameters, thus permitting the calculation of t statistics.
‡Attribute levels were insigniﬁcant in regression, thus WTP is not signiﬁcantly different from zero.
§Wald test indicates a signiﬁcant difference between coefﬁcients.
||Variables are dummy coded 1 if equal to descriptor and 0 otherwise.
WTP, willingness to pay; GUM, genitourinary medicine; PID, pelvic inﬂammatory disease.
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support of a trained health-care provider when receiving their
results. These screening experience factors inﬂuence the value
that recipients place on tests—a fact that should be reﬂected in
cost-effectiveness studies. Respondents under 25 years and
those in a casual relationship were less likely to be screened.
This is a cause for concern because this age group has the
highest prevalence rates of chlamydia and women in a casual
relationship are at a higher risk of infection than those who are
single or in a permanent relationship.
Our study has a number of limitations that may affect the
generalizability of the results. First, respondents were recruited at
a family planning clinic, perhaps explaining the general prefer-
ence for the family planning clinic location. Evidence suggests
that the treatment that is experienced is preferred [9] and that
subjects recruited in other clinical settings may respond differ-
ently to the DCE. Currently, those who test positive are referred
to GUM clinics for follow-up screening 3 and 6 months after
diagnosis and treatment. Nevertheless, if individuals prefer their
status quo, then uptake of follow-up screening may be increased
if they are asked to return to the familiar location of their original
screening test rather than being referred to another clinic.
Second, we do not have information about those who did not
participate in the study, thus we can not comment on, or control
for, nonresponse bias. That said, the respondents’ demographics
do reﬂect the target population for chlamydia screening. Third,
the attributes were not chosen using input from potential users.
Future work should explore if other attributes are important to
this group to maximize the chances of increasing uptake. Fourth,
the insigniﬁcance of the risk of pelvic inﬂammatory disease may
reﬂect the difﬁculties that respondents had in understanding this
attribute as it represented a risk conditional on two factors:
having chlamydia and not being treated. Future work should
explore this in more detail.
Cost-effectiveness studies focusing on purposive sampling
using “mail-from-home” tests ﬁnd that screening is not cost-
effective [2]. We ﬁnd “at-home” screening is the least preferred
location. This result is consistent with a review of screening
outside “clinic” settings, which found lower uptake for home-
based screening [10]. Furthermore, we ﬁnd there is value
in the screening process (type of test, location, and support), and
there is a general value in screening which may reﬂect the value
of information. Although there are a number of limitations of
this study, an important message emerges: Failure to take account
of factors, referred to here as experience factors, could result in
misleading recommendations regarding the efﬁciency of chlamy-
dia screening.
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Table 2 Characteristics of the respondents
Characteristic Sample (%)
Age (years)
14–18 26.2
19–21 34.5
22–25 22.1
26+ 17.2
Employment
Part-time 18.8
Full-time 31.7
Student 45.1
Other 4.6
Education
S grade (=GCSE) 20.1
H grade (= A level) 23.1
Vocational 30.2
University degree 26.6
Income (£)
Less than 5000 24.7
5,000–10,000 16.3
10,001–15,000 10.1
15,001–20,000 21.7
20,001–30,000 14.0
Over 30,000 13.2
Method of contraception
Barrier 39.8
Nonbarrier 60.2
Relationship status
Single 29.2
Married 1.5
Permanent relationship 46.7
Casual relationship 22.6
Smoker
Yes 46.8
No 53.2
Previously received a diagnosis of chlamydia
Yes 13.1
No 86.9
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